British American Tobacco Plc CFO Soraya Benchikh to step down

British American Tobacco

British American Tobacco Plc (LON:BATS) has announced that Soraya Benchikh is stepping down from her role as Chief Financial Officer and from the Board of Directors of the Company with effect from 26 August 2025.  Soraya will remain available to support the transition until 31 December 2025.

A recruitment process to identify a permanent successor to the role of Chief Financial Officer is being launched. Javed Iqbal, who is currently Director, Digital and Information, will take on the role of interim Chief Financial Officer. Javed recently acted as the Company’s Interim Finance Director from May 2023 until April 2024.

Tadeu Marroco, British American Tobacco Chief Executive, commented:

“Soraya has made a significant contribution to BAT, having worked in various roles within the Group over many years. On behalf of the Board, I would like to thank Soraya for her contribution, most recently in her role as Chief Financial Officer since rejoining the Group in May 2024. We wish her all the best with her future plans.

As we set out at our recent results, our performance in the first half of the year was slightly ahead of our expectations, and we are firmly on track to deliver our full year guidance. With the right strategy we intend to continue to deliver on the profitable transformation of BAT, reflected in our stated ambitions for 2026 and beyond.  We will update on our continued progress in our pre-close trading update in December.”

Soraya Benchikh commented:

“I am proud of my role in the significant progress since I joined BAT, as reflected in our recent results.

Further embedding financial discipline and putting New Categories on a path to accretive margins and sustainable profitability have been key contributions to that progress. This was made possible thanks to the incredibly talented and dedicated teams I have had the privilege to work with across BAT. Now is the right time for me to move on to my next transformation. I wish the BAT team every success in taking the business to the next level.”

Supplementary Information – Remuneration

All remuneration arrangements are consistent with the terms of the Directors’ Remuneration Policy approved by shareholders at the AGM in April 2025. 

In accordance with section 430(2B) of the Companies Act 2006, information in respect of Soraya Benchikh’s departure from the Board will be available on bat.com in due course and will remain available until the Company’s Directors’ Remuneration Report in the Annual Report for the year ended 31 December 2025 is made available.

Share on:

Latest Company News

Valeura Energy accelerates Wassana first oil as 2027 production outlook improves, Auctus Advisors

Valeura Energy accelerates Wassana first oil as Auctus Advisors forecasts higher 2027 production, cash flow and development potential.

Manx Financial reports strong H1 operational growth

Manx Financial Group reports continued growth across Conister Bank and Payment Assist in H1 2026, alongside progress on AI-driven efficiencies, new products and strategic investment opportunities.

Cora Gold reports transformational H1 2026, Sanankoro advances toward construction

Cora Gold reports interim results for the six months ended 30 June 2026, highlighting a £15.7 million equity raise, a US$120 million gold stream, commencement of FEED and a 12,000-metre drilling programme at Sanankoro. Post-period, the Sanankoro II exploration permit was renewed as the project progresses toward construction.

Elemental Royalty expands gold exposure through a diversified royalty portfolio

Elemental Royalty is building a diversified portfolio of producing and development-stage mining royalties focused primarily on gold.

Gold price rises as dollar and US bond yields fall

Gold prices rise as the US dollar and Treasury yields fall, with markets turning to US employment data for the next major signal.

Sanofi deepens respiratory franchise as earnings expectations come into focus

Sanofi is expanding respiratory market access in Spain through Dupixent and Beyfortus as attention turns to product adoption, public healthcare demand and the company’s earnings outlook.

    Search